Novo Nordisk and Septerna Forge Groundbreaking $2.2 Billion Partnership to Revolutionize Obesity and Diabetes Treatment

Novo Nordisk and Septerna have entered a $2.2 billion partnership to develop oral treatments for obesity and type 2 diabetes, combining Danish research excellence with U.S. biotech...